GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA Psychiatry, researchers report that semaglutide, better known as Ozempic or Wegovy, helped people with alcohol addiction reduce their craving and drink less.

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super Bowl ad, leveling the accusation against brand-name weight loss drugs. Set to the tune of Childish Gambino’s “This Is America,

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research into its broader health impacts.

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Weight loss drugs continue to make headlines.  A new study conducted by researchers from the University of Southern California looked at a positive side

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Millions of Americans use GLP-1 injections like Ozempic to lose weight. A study is questioning whether they can cause vision loss.